TrialAnnals of the rheumatic diseases2009

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

R Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.